Difference between revisions of "Part:BBa K404153"
 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
 
<partinfo>BBa_K404153 short</partinfo>
 
<partinfo>BBa_K404153 short</partinfo>
 +
<br/><br><br>
 +
{| style="color:black" cellpadding="6" cellspacing="1" border="2" align="left"
 +
! colspan="2" style="background:#66bbff;"|[https://parts.igem.org/Part:BBa_K404153 [AAV2]-NLS]
 +
|-
 +
|'''BioBrick Nr.'''
 +
|[https://parts.igem.org/Part:BBa_K404123 BBa_K404153]
 +
|-
 +
|'''RFC standard'''
 +
|[https://parts.igem.org/Help:Assembly_standard_25 RFC 25]
 +
|-
 +
|'''Requirement'''
 +
|pSB1C3<br>
 +
|-
 +
|'''Source'''
 +
|pAAV_MCS: provided by Stratagene<br/>
 +
|-
 +
|'''Submitted by'''
 +
|[http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010]
 +
|}
 +
<br><br><br><br><br><br><br><br><br><br><br><br><br>
 +
<h3>General informations</h3>
 +
<html>
 +
<center>
 +
<img src=https://static.igem.org/mediawiki/2010/e/e8/Freiburg10_VP1-3_overview.jpg width=400>
 +
</center>
 +
</html><br>
 +
The AAV capsid consists of 60 capsid protein subunits composed of the three cap proteins VP1, VP2, and VP3, which are encoded in an overlapping reading frame. Arranged in a stoichiometric ratio of 1:1:10, they form an icosahedral symmetry. The mRNA encoding for the cap proteins is transcribed from p40 and alternative spliced to minor and major products. Alternative splicing and translation initiation of VP2 at a nonconventional ACG initiation codon promote the expression of the VP proteins. VP1, VP2 and VP3 share a common C terminus and stop codon, but begin with a different start codon. The N termini of VP1 and VP2 play important roles in infection and contain motifs that are highly homologous to a phospholipase A2 (PLA2) domain and nuclear localization signals (NLS, see basic regions). These elements are conserved in almost all parvoviruses. (Johnson et al., 2010a). <br/>
 +
<br/>
 +
Whereas VP1 is translated from the minor spliced mRNA, while VP2 and VP3 are translated from the major spliced mRNA. The minor spliced product is approximately 10-fold less abundant than the major spliced mRNA. Thus, there is much less VP1 than VP2 and VP3 resulting in a capsid  stoichiometric ratio of 1:1:10. The N terminus of VP1 has an extension of 65 amino acids including an additional extension of 138 N-terminal amino acids forming the unique portion of VP1. It contains a motif of about 70 amino acids that is highly homologous to  phospholipase A2 (PLA2) domain.  Furthermore, there are nuclear localization sequences (BR)(+), which are supposed to be necessary for endosomal escape and nuclear entry. (Bleker, Pawlita, & Kleinschmidt, 2006), (DiPrimio, Asokan, Govindasamy, Agbandje-McKenna, & Samulski, 2008), (Johnson et al., 2010a). <br />
 +
<br/>
 +
The translation of VP2 from the major spliced mRNA is less efficient compared to the translation of VP3 because it initiates at  Thr codon (ACG). VP2 and VP1 have an extension at the N terminus that remains internal when exposing the capsid to experimental conditions like low pH or heat. The exact role of VP2 remains unknown, although the protein is thought to be nonessential for viral assembly and infectivity. (DiPrimio, Asokan, Govindasamy, Agbandje-McKenna, & Samulski, 2008), (Johnson et al., 2010b)
  
−
NLS are located in basic residues and are hydrophilic and contain ß-turn and coil regions [Kalderon, et al, 1984]. NLS were described also in CPV and MVM viruses. Compared to CPV, MVM virus contains several NLS within the capsid, which are activated at different infection stages [Lombardo et al., 2000; Lombardo et al., 2002]
+
<h3>NLS</h3>
 +
NLS are located in basic regions on the N terminus of VP2 (35 aa) and VP1 (172 aa) and mediate genome delivery into the nucleus and transduction [Hoque et al.,1999; Grieger et al., 2006]. Nuclear localisation sequence is hydrophilic and contains ß-turn and coil regions [Kalderon, et al, 1984]. It was also described in CPV and MVM viruses. Compared to CPV, MVM virus contains several NLS within the capsid, which are activated at different infection stages [Lombardo et al., 2000; Lombardo et al., 2002]
 +
 
 +
<html>
 +
<head>
 +
<meta http-equiv="Content-Type"
 +
content="text/html; charset=windows-1252">
 +
<meta name="Generator" content="Microsoft Word 14 (filtered)">
 +
<style>
 +
<!--
 +
/* Font Definitions */
 +
@font-face
 +
{font-family:Cambria;
 +
panose-1:2 4 5 3 5 4 6 3 2 4;}
 +
@font-face
 +
{font-family:Calibri;
 +
panose-1:2 15 5 2 2 2 4 3 2 4;}
 +
@font-face
 +
{font-family:Tahoma;
 +
panose-1:2 11 6 4 3 5 4 4 2 4;}
 +
/* Style Definitions */
 +
p.MsoNormal, li.MsoNormal, div.MsoNormal
 +
{margin-top:0cm;
 +
margin-right:0cm;
 +
margin-bottom:12.0pt;
 +
margin-left:0cm;
 +
text-align:justify;
 +
text-indent:17.85pt;
 +
line-height:200%;
 +
font-size:11.0pt;
 +
font-family:"Calibri","sans-serif";}
 +
h1
 +
{mso-style-link:"Heading 1 Char";
 +
margin-top:30.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:21.6pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-21.6pt;
 +
line-height:150%;
 +
border:none;
 +
padding:0cm;
 +
font-size:16.0pt;
 +
font-family:"Calibri","sans-serif";}
 +
h2
 +
{mso-style-link:"Heading 2 Char";
 +
margin-top:16.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:28.8pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-28.8pt;
 +
line-height:150%;
 +
font-size:14.0pt;
 +
font-family:"Calibri","sans-serif";
 +
color:#002060;}
 +
h3
 +
{mso-style-link:"Heading 3 Char";
 +
margin-top:16.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:36.0pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-36.0pt;
 +
line-height:150%;
 +
font-size:13.0pt;
 +
font-family:"Calibri","sans-serif";
 +
color:red;}
 +
h4
 +
{mso-style-link:"Heading 4 Char";
 +
margin-top:14.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:43.2pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-43.2pt;
 +
line-height:150%;
 +
font-size:12.0pt;
 +
font-family:"Calibri","sans-serif";
 +
color:#00B050;}
 +
h5
 +
{mso-style-link:"Heading 5 Char";
 +
margin-top:14.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:50.4pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-50.4pt;
 +
line-height:150%;
 +
font-size:11.0pt;
 +
font-family:"Calibri","sans-serif";}
 +
h6
 +
{mso-style-link:"Heading 6 Char";
 +
margin-top:14.0pt;
 +
margin-right:0cm;
 +
margin-bottom:4.0pt;
 +
margin-left:57.6pt;
 +
text-align:justify;
 +
text-indent:-57.6pt;
 +
line-height:150%;
 +
font-size:11.0pt;
 +
font-family:"Cambria","serif";
 +
font-style:italic;}
 +
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
 +
{mso-style-link:"Heading 7 Char";
 +
margin-top:14.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:64.8pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-64.8pt;
 +
line-height:150%;
 +
font-size:10.0pt;
 +
font-family:"Cambria","serif";
 +
font-weight:bold;
 +
font-style:italic;}
 +
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
 +
{mso-style-link:"Heading 8 Char";
 +
margin-top:14.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:72.0pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-72.0pt;
 +
line-height:150%;
 +
font-size:9.0pt;
 +
font-family:"Cambria","serif";
 +
font-weight:bold;
 +
font-style:italic;}
 +
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
 +
{mso-style-link:"Heading 9 Char";
 +
margin-top:14.0pt;
 +
margin-right:0cm;
 +
margin-bottom:0cm;
 +
margin-left:79.2pt;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:-79.2pt;
 +
line-height:150%;
 +
font-size:9.0pt;
 +
font-family:"Cambria","serif";
 +
font-style:italic;}
 +
a:link, span.MsoHyperlink
 +
{color:blue;
 +
text-decoration:underline;}
 +
a:visited, span.MsoHyperlinkFollowed
 +
{color:purple;
 +
text-decoration:underline;}
 +
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
 +
{mso-style-link:"Balloon Text Char";
 +
margin:0cm;
 +
margin-bottom:.0001pt;
 +
text-align:justify;
 +
text-indent:17.85pt;
 +
font-size:8.0pt;
 +
font-family:"Tahoma","sans-serif";}
 +
span.BalloonTextChar
 +
{mso-style-name:"Balloon Text Char";
 +
mso-style-link:"Balloon Text";
 +
font-family:"Tahoma","sans-serif";}
 +
span.Heading1Char
 +
{mso-style-name:"Heading 1 Char";
 +
mso-style-link:"Heading 1";
 +
font-family:"Calibri","sans-serif";
 +
font-weight:bold;}
 +
span.Heading2Char
 +
{mso-style-name:"Heading 2 Char";
 +
mso-style-link:"Heading 2";
 +
font-family:"Calibri","sans-serif";
 +
color:#002060;
 +
font-weight:bold;}
 +
span.Heading3Char
 +
{mso-style-name:"Heading 3 Char";
 +
mso-style-link:"Heading 3";
 +
font-family:"Calibri","sans-serif";
 +
color:red;
 +
font-weight:bold;}
 +
span.Heading4Char
 +
{mso-style-name:"Heading 4 Char";
 +
mso-style-link:"Heading 4";
 +
font-family:"Calibri","sans-serif";
 +
color:#00B050;
 +
font-weight:bold;}
 +
span.Heading5Char
 +
{mso-style-name:"Heading 5 Char";
 +
mso-style-link:"Heading 5";
 +
font-family:"Calibri","sans-serif";
 +
font-weight:bold;}
 +
span.Heading6Char
 +
{mso-style-name:"Heading 6 Char";
 +
mso-style-link:"Heading 6";
 +
font-family:"Cambria","serif";
 +
font-weight:bold;
 +
font-style:italic;}
 +
span.Heading7Char
 +
{mso-style-name:"Heading 7 Char";
 +
mso-style-link:"Heading 7";
 +
font-family:"Cambria","serif";
 +
font-weight:bold;
 +
font-style:italic;}
 +
span.Heading8Char
 +
{mso-style-name:"Heading 8 Char";
 +
mso-style-link:"Heading 8";
 +
font-family:"Cambria","serif";
 +
font-weight:bold;
 +
font-style:italic;}
 +
span.Heading9Char
 +
{mso-style-name:"Heading 9 Char";
 +
mso-style-link:"Heading 9";
 +
font-family:"Cambria","serif";
 +
font-style:italic;}
 +
span.apple-style-span
 +
{mso-style-name:apple-style-span;}
 +
span.apple-converted-space
 +
{mso-style-name:apple-converted-space;}
 +
.MsoChpDefault
 +
{font-family:"Calibri","sans-serif";}
 +
.MsoPapDefault
 +
{margin-bottom:10.0pt;
 +
line-height:115%;}
 +
@page WordSection1
 +
{size:595.3pt 841.9pt;
 +
margin:70.85pt 70.85pt 2.0cm 70.85pt;}
 +
div.WordSection1
 +
{page:WordSection1;}
 +
/* List Definitions */
 +
ol
 +
{margin-bottom:0cm;}
 +
ul
 +
{margin-bottom:0cm;}
 +
-->
 +
</style>
 +
</head>
 +
<body lang="DE" link="blue" vlink="purple">
 +
<div class="WordSection1">
 +
<h2><span lang="EN-US">Characterization</span></h2>
 +
<br>
 +
<p class="MsoNormal"
 +
style="margin-bottom: 10pt; text-indent: 0cm; line-height: 150%;"><span
 +
style="color: black;" lang="EN-US">Specific targeting of tumor cells
 +
was, besides producing recombinant Adeno-associated virus 2 (AAV2)
 +
particles
 +
for therapeutical applications, one intention of the Virus Construction
 +
Kit
 +
provided by the iGEM team Freiburg_Bioware 2010.</span></p>
 +
<p class="MsoNormal"
 +
style="margin-bottom: 10pt; text-indent: 0cm; line-height: 150%;"><span
 +
style="color: black;" lang="EN-US">Besides fusing larger motifs to the
 +
N-terminus of the viral protein 2 (VP2) open reading frame (ORF), we
 +
designed a
 +
method for inserting into VP1. It is expected that these peptides
 +
become
 +
located on the virus surface either by transit through the pores or by
 +
exposure
 +
during capsid assembly.</span></p>
 +
<p class="MsoNormal"
 +
style="margin-bottom: 10pt; text-indent: 0cm; line-height: 150%;"><span
 +
style="color: black;" lang="EN-US">This part was created in order to
 +
be
 +
fused to the desired surface exposed motif before cloning into VP1,
 +
promising
 +
better infectivity of the AAV2 therapeutic vectors</span><span
 +
class="apple-converted-space"><span style="color: black;" lang="EN-US">&nbsp;</span></span><span
 +
class="apple-style-span"><span style="color: black;" lang="EN-US">(Grieger
 +
et al.,
 +
2007)</span></span><span style="color: black;" lang="EN-US">.</span></p>
 +
<h4><span style="font-size: 11pt; line-height: 150%;" lang="EN-US">&nbsp;</span></h4>
 +
<h4><span lang="EN-US">Nuclear Localization by Fluorescence Microscopy</span></h4>
 +
<br>
 +
<p class="MsoNormal" style="text-indent: 0cm; line-height: 150%;"><span
 +
lang="EN-US">The
 +
</span><span style="color: black;" lang="EN-US">iGEM team
 +
Freiburg_Bioware 2010
 +
tested the efficacy of this part by cloning it together with mVenus
 +
into VP1. </span></p>
 +
<p class="MsoNormal" style="text-indent: 0cm; line-height: 150%;"><span
 +
lang="EN-US">AAV-293
 +
cells were transfected with a 50:50 ratio of the Rep/Cap(VP1KO) to the
 +
CMV_VP1_NLS_mVenus_VP2/3 plasmid. We packaged mCherry, driven by the
 +
CMV
 +
promoter, into the virus capsids and followed protein expression via
 +
fluorescence microscopy. 30 hours post transfection mCherry
 +
fluorescence was
 +
detectable in the whole cytosol of the successfully transfected cells,
 +
demonstrating that DNA located between the AAV2 ITRs is already
 +
transcribed in
 +
the producer cell line. In contrast to that mVenus fluorescence signal
 +
could be
 +
observed only in the nuclei (Fig. 1). This indicated that the nuclear
 +
localization sequence targets the single VP1_NLS_mVenus_VP2/3 proteins
 +
efficiently to the cell nucleus, where assembly and packaging of the
 +
virus
 +
particles takes place.&nbsp;</span></p>
 +
<table class="MsoTableGrid"
 +
style="border: medium none ; border-collapse: collapse; width: 572px; height: 500px; text-align: left; margin-left: auto; margin-right: auto;"
 +
border="0" cellpadding="0" cellspacing="0">
 +
<tbody>
 +
<tr style="height: 368.05pt;">
 +
<td
 +
style="padding: 0cm 5.4pt; vertical-align: top; width: 446.15pt; height: 368.05pt;">
 +
<p class="MsoNormal"
 +
style="margin-bottom: 0.0001pt; text-indent: 0cm; line-height: 150%;"><br>
 +
</p>
 +
<div style="text-align: center;">&nbsp;<img alt="timelapse"
 +
src="https://static.igem.org/mediawiki/parts/thumb/6/65/Freiburg10_NLS_mVenus_mCherry.png/800px-Freiburg10_NLS_mVenus_mCherry.png"
 +
style="width: 500px; height: 375px;"></div>
 +
<p class="MsoNormal"
 +
style="margin-bottom: 0.0001pt; text-indent: 0cm; line-height: 150%;"><br>
 +
</p>
 +
<p class="MsoNormal"
 +
style="text-indent: 0cm; line-height: normal; text-align: justify;"><b><span
 +
style="font-size: 10pt;" lang="EN-US">Figure 1: Fluorescence
 +
Microscopy. A) </span></b><span style="font-size: 10pt;" lang="EN-US">Brightfiled
 +
picture. <b>B)</b> Excitation at 555 nm showed mCherry signal in the
 +
cytosol. <b>C)</b> Excitation at 505 nm revealed mVenus fluorescence
 +
in the nuclei, indicating functionality of the nuclear localization
 +
sequence inserted – together with mVenus – into VP1. <b>D)</b> Merged
 +
image.</span></p>
 +
</td>
 +
</tr>
 +
</tbody>
 +
</table>
 +
<p class="MsoNormal"><span style="font-size: 12pt; line-height: 150%;"
 +
lang="EN-US">&nbsp;</span>&nbsp;</p>
 +
</div>
 +
</body>
 +
</html>
  
−
<!-- Add more about the biology of this part here
 
−
===Usage and Biology===
 
  
 
<!-- -->
 
<!-- -->
Line 17: Line 379:
 
<!-- -->
 
<!-- -->
 
<h3>References</h3>
 
<h3>References</h3>
 +
<b>Bleker, S., Pawlita, M., & Kleinschmidt, J.</b>, 2006. IImpact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. Journal of virology, 80(2), 810-820. doi: 10.1128/JVI.80.2.810. <br />
 +
<b>DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. </b>, 2008. Surface loop dynamics in adeno-associated virus capsid assembly. Journal of virology, 82(11), 5178-89. doi: 10.1128/JVI.02721-07. <br />
 +
<b>Grieger et al.</b>, (2007). Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol. 2007 Aug;81(15):7833-43. Epub 2007 May 16.<br/>
 +
<b>Hoque</b>, 1999. Nuclear transport of the major capsid protein is essential for adeno-associated virus capsid formation. Journal of Virology, 73(9), pp.7912-7915. <br />
 
<b>Kalderon, D</b>, 1984. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature, 311(5981), pp.33-38 <br />
 
<b>Kalderon, D</b>, 1984. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature, 311(5981), pp.33-38 <br />
 +
<b>Johnson, J.S.</b>, 2010. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. Journal of virology, 84(17), 8888-902. doi: 10.1128/JVI.00687-10.<br />
 
<b>Lombardo, E</b>, 2000. A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. Journal of Virology, 74(8), pp.3804-3814 <br />
 
<b>Lombardo, E</b>, 2000. A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. Journal of Virology, 74(8), pp.3804-3814 <br />
 
<b>Lombardo, E </b>, 2002. Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. Journal of Virology, 76(14), pp.7049-7059
 
<b>Lombardo, E </b>, 2002. Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. Journal of Virology, 76(14), pp.7049-7059

Latest revision as of 15:21, 31 October 2010

[AAV2]-NLS


[AAV2-NLS]
BioBrick Nr. BBa_K404153
RFC standard RFC 25
Requirement pSB1C3
Source pAAV_MCS: provided by Stratagene
Submitted by [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010]














General informations


The AAV capsid consists of 60 capsid protein subunits composed of the three cap proteins VP1, VP2, and VP3, which are encoded in an overlapping reading frame. Arranged in a stoichiometric ratio of 1:1:10, they form an icosahedral symmetry. The mRNA encoding for the cap proteins is transcribed from p40 and alternative spliced to minor and major products. Alternative splicing and translation initiation of VP2 at a nonconventional ACG initiation codon promote the expression of the VP proteins. VP1, VP2 and VP3 share a common C terminus and stop codon, but begin with a different start codon. The N termini of VP1 and VP2 play important roles in infection and contain motifs that are highly homologous to a phospholipase A2 (PLA2) domain and nuclear localization signals (NLS, see basic regions). These elements are conserved in almost all parvoviruses. (Johnson et al., 2010a).

Whereas VP1 is translated from the minor spliced mRNA, while VP2 and VP3 are translated from the major spliced mRNA. The minor spliced product is approximately 10-fold less abundant than the major spliced mRNA. Thus, there is much less VP1 than VP2 and VP3 resulting in a capsid stoichiometric ratio of 1:1:10. The N terminus of VP1 has an extension of 65 amino acids including an additional extension of 138 N-terminal amino acids forming the unique portion of VP1. It contains a motif of about 70 amino acids that is highly homologous to phospholipase A2 (PLA2) domain. Furthermore, there are nuclear localization sequences (BR)(+), which are supposed to be necessary for endosomal escape and nuclear entry. (Bleker, Pawlita, & Kleinschmidt, 2006), (DiPrimio, Asokan, Govindasamy, Agbandje-McKenna, & Samulski, 2008), (Johnson et al., 2010a).

The translation of VP2 from the major spliced mRNA is less efficient compared to the translation of VP3 because it initiates at Thr codon (ACG). VP2 and VP1 have an extension at the N terminus that remains internal when exposing the capsid to experimental conditions like low pH or heat. The exact role of VP2 remains unknown, although the protein is thought to be nonessential for viral assembly and infectivity. (DiPrimio, Asokan, Govindasamy, Agbandje-McKenna, & Samulski, 2008), (Johnson et al., 2010b)

NLS

NLS are located in basic regions on the N terminus of VP2 (35 aa) and VP1 (172 aa) and mediate genome delivery into the nucleus and transduction [Hoque et al.,1999; Grieger et al., 2006]. Nuclear localisation sequence is hydrophilic and contains ß-turn and coil regions [Kalderon, et al, 1984]. It was also described in CPV and MVM viruses. Compared to CPV, MVM virus contains several NLS within the capsid, which are activated at different infection stages [Lombardo et al., 2000; Lombardo et al., 2002]

Characterization


Specific targeting of tumor cells was, besides producing recombinant Adeno-associated virus 2 (AAV2) particles for therapeutical applications, one intention of the Virus Construction Kit provided by the iGEM team Freiburg_Bioware 2010.

Besides fusing larger motifs to the N-terminus of the viral protein 2 (VP2) open reading frame (ORF), we designed a method for inserting into VP1. It is expected that these peptides become located on the virus surface either by transit through the pores or by exposure during capsid assembly.

This part was created in order to be fused to the desired surface exposed motif before cloning into VP1, promising better infectivity of the AAV2 therapeutic vectors (Grieger et al., 2007).

 

Nuclear Localization by Fluorescence Microscopy


The iGEM team Freiburg_Bioware 2010 tested the efficacy of this part by cloning it together with mVenus into VP1.

AAV-293 cells were transfected with a 50:50 ratio of the Rep/Cap(VP1KO) to the CMV_VP1_NLS_mVenus_VP2/3 plasmid. We packaged mCherry, driven by the CMV promoter, into the virus capsids and followed protein expression via fluorescence microscopy. 30 hours post transfection mCherry fluorescence was detectable in the whole cytosol of the successfully transfected cells, demonstrating that DNA located between the AAV2 ITRs is already transcribed in the producer cell line. In contrast to that mVenus fluorescence signal could be observed only in the nuclei (Fig. 1). This indicated that the nuclear localization sequence targets the single VP1_NLS_mVenus_VP2/3 proteins efficiently to the cell nucleus, where assembly and packaging of the virus particles takes place. 


 timelapse


Figure 1: Fluorescence Microscopy. A) Brightfiled picture. B) Excitation at 555 nm showed mCherry signal in the cytosol. C) Excitation at 505 nm revealed mVenus fluorescence in the nuclei, indicating functionality of the nuclear localization sequence inserted – together with mVenus – into VP1. D) Merged image.

  


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


References

Bleker, S., Pawlita, M., & Kleinschmidt, J., 2006. IImpact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. Journal of virology, 80(2), 810-820. doi: 10.1128/JVI.80.2.810.
DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. , 2008. Surface loop dynamics in adeno-associated virus capsid assembly. Journal of virology, 82(11), 5178-89. doi: 10.1128/JVI.02721-07.
Grieger et al., (2007). Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol. 2007 Aug;81(15):7833-43. Epub 2007 May 16.
Hoque, 1999. Nuclear transport of the major capsid protein is essential for adeno-associated virus capsid formation. Journal of Virology, 73(9), pp.7912-7915.
Kalderon, D, 1984. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature, 311(5981), pp.33-38
Johnson, J.S., 2010. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. Journal of virology, 84(17), 8888-902. doi: 10.1128/JVI.00687-10.
Lombardo, E, 2000. A beta-stranded motif drives capsid protein oligomers of the parvovirus minute virus of mice into the nucleus for viral assembly. Journal of Virology, 74(8), pp.3804-3814
Lombardo, E , 2002. Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. Journal of Virology, 76(14), pp.7049-7059